{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:25:56Z","timestamp":1767176756361,"version":"build-2238731810"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1012839","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000}}],"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Antibody-drug conjugates (ADCs) are gaining increasing traction in the treatment of oncological diseases; however, many clinical failures have also been observed. One key factor limiting ADC effectiveness is the heterogeneous expression of their target antigen. While the vast majority of ADCs in clinical development target antigens on cancer cells (cancer-targeting), they can also target antigens expressed on non-cancerous stromal cells in the tumor microenvironment (stroma-targeting). It remains unclear if ADCs targeting stromal cells can outperform cancer-targeting ADCs. Here, we present three related mathematical models to evaluate: (1) cancer-targeting ADCs with homogeneous target antigen expression, (2) cancer-targeting ADCs with heterogeneous target antigen expression, and (3) stroma-targeting ADCs. Our simulations suggest that cancer-targeting ADCs can achieve high efficacy when their target antigen is homogenously expressed. However, in cases of heterogeneous antigen expression, cancer-targeting ADCs may lead to an initial reduction in tumor size, followed by regrowth due to the elimination of antigen-positive cells and expansion of antigen-negative cells. This limitation could potentially be overcome by stroma-targeting ADCs, as antigen-positive stromal cells may continue to be recruited into the tumor by the oncogenic factors produced by the remaining cancer cells. Furthermore, we demonstrate that ADCs with more permeable payloads and less stable linkers may offer improved efficacy in the context of heterogeneous target expression.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1012839","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T18:30:17Z","timestamp":1755109817000},"page":"e1012839","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target exspression"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1874-9226","authenticated-orcid":true,"given":"N. Ezgi","family":"Wood","sequence":"first","affiliation":[]},{"given":"An\u0131l","family":"Cengiz","sequence":"additional","affiliation":[]},{"given":"Ming","family":"Gao","sequence":"additional","affiliation":[]},{"given":"Alexander V.","family":"Ratushny","sequence":"additional","affiliation":[]},{"given":"Ronny","family":"Straube","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"3","key":"pcbi.1012839.ref001","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"K Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"pcbi.1012839.ref002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"C Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"pcbi.1012839.ref003","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates--an emerging class of cancer treatment","volume":"114","author":"N Diamantis","year":"2016","journal-title":"Br J Cancer"},{"issue":"1","key":"pcbi.1012839.ref004","first-page":"1","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Z Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"pcbi.1012839.ref005","doi-asserted-by":"crossref","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Y Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"1","key":"pcbi.1012839.ref006","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2012drug conjugates in human cancers","volume":"23","author":"K Liu","year":"2024","journal-title":"Mol Cancer"},{"issue":"2","key":"pcbi.1012839.ref007","doi-asserted-by":"crossref","first-page":"252","DOI":"10.37349\/etat.2022.00082","article-title":"Antibody-drug conjugates: beyond current approvals and potential future strategies","volume":"3","author":"S Menon","year":"2022","journal-title":"Explor Target Antitumor Ther"},{"issue":"13","key":"pcbi.1012839.ref008","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-20-4513","article-title":"First-in-human phase I study of ABBV-085, an antibody-drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors","volume":"27","author":"GD Demetri","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"12","key":"pcbi.1012839.ref009","doi-asserted-by":"crossref","first-page":"104241","DOI":"10.1016\/j.drudis.2024.104241","article-title":"Antibody-drug conjugates: prospects for the next generation","volume":"29","author":"M Grairi","year":"2024","journal-title":"Drug Discov Today"},{"issue":"11","key":"pcbi.1012839.ref010","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody\u2013drug conjugates: lessons learned from 40 years of development","volume":"14","author":"R Colombo","year":"2024","journal-title":"Cancer Discov"},{"issue":"11","key":"pcbi.1012839.ref011","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","article-title":"The therapeutic window of antibody drug conjugates: a dogma in need of revision","volume":"40","author":"R Colombo","year":"2022","journal-title":"Cancer Cell"},{"issue":"8","key":"pcbi.1012839.ref012","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/psp4.12833","article-title":"Development of and insights from systems pharmacology models of antibody-drug conjugates","volume":"11","author":"I Lam","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"pcbi.1012839.ref013","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12885-019-5336-7","article-title":"Modeling to capture bystander-killing effect by released payload in target positive tumor cells","volume":"19","author":"JH Byun","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"pcbi.1012839.ref014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1039\/C7ME00093F","article-title":"Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy","volume":"3","author":"E Khera","year":"2018","journal-title":"Mol Syst Des Eng"},{"issue":"5","key":"pcbi.1012839.ref015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10928-023-09884-6","article-title":"Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)","volume":"51","author":"B Scheuher","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"pcbi.1012839.ref016","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10928-012-9276-y","article-title":"Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK\/PD model: a case study with brentuximab-vedotin","volume":"39","author":"DK Shah","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"pcbi.1012839.ref017","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.xphs.2019.01.034","article-title":"A \u201cdual\u201d cell-level systems PK-PD model to characterize the bystander effect of ADC","volume":"108","author":"AP Singh","year":"2019","journal-title":"J Pharm Sci"},{"issue":"1","key":"pcbi.1012839.ref018","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12935-022-02599-7","article-title":"Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures","volume":"22","author":"B Feng","year":"2022","journal-title":"Cancer Cell Int"},{"key":"pcbi.1012839.ref019","article-title":"CAFs orchestrates tumor immune microenvironment\u2014A new target in cancer therapy?","volume":"14","author":"C Zhang","year":"2023","journal-title":"Front Pharmacol"},{"issue":"3","key":"pcbi.1012839.ref020","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1158\/0008-5472.CAN-03-2524","article-title":"Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents","volume":"64","author":"M Simeoni","year":"2004","journal-title":"Cancer Res"},{"issue":"5","key":"pcbi.1012839.ref021","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"A Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"pcbi.1012839.ref022","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ddtec.2018.07.002","article-title":"Minireview: addressing the retro-Michael instability of maleimide bioconjugates","volume":"30","author":"PA Szijj","year":"2018","journal-title":"Drug Discov Today Technol"},{"issue":"7","key":"pcbi.1012839.ref023","first-page":"2527","article-title":"A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies","volume":"9","author":"MA Garrison","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"7","key":"pcbi.1012839.ref024","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"TN Iwata","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"6586","key":"pcbi.1012839.ref025","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay9040","article-title":"Early detection of cancer","volume":"375","author":"D Crosby","year":"2022","journal-title":"Science"},{"issue":"24","key":"pcbi.1012839.ref026","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2007.14.3065","article-title":"New technologies for human cancer imaging","volume":"26","author":"JV Frangioni","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"pcbi.1012839.ref027","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"F Li","year":"2016","journal-title":"Cancer Res"},{"issue":"14","key":"pcbi.1012839.ref028","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","article-title":"LRRC15 is a novel mesenchymal protein and stromal target for antibody\u2013drug conjugates","volume":"78","author":"JW Purcell","year":"2018","journal-title":"Cancer Res"},{"issue":"3","key":"pcbi.1012839.ref029","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"TD Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"pcbi.1012839.ref030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"MA Jordan","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"pcbi.1012839.ref031","first-page":"11","article-title":"Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors","volume":"1835","author":"MT Tomicic","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"pcbi.1012839.ref032","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00428-018-2408-z","article-title":"Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations","volume":"473","author":"GW van Pelt","year":"2018","journal-title":"Virchows Arch"},{"issue":"11","key":"pcbi.1012839.ref033","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nri3902","article-title":"Immunological hallmarks of stromal cells in the tumour microenvironment","volume":"15","author":"SJ Turley","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"pcbi.1012839.ref034","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"LC Tsao","year":"2025","journal-title":"Nat Commun"},{"issue":"12","key":"pcbi.1012839.ref035","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Z Su","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"pcbi.1012839.ref036","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Z Wang","year":"2023","journal-title":"Acta Pharm Sin B"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1012839","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1012839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:59:07Z","timestamp":1755799147000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1012839"}},"subtitle":[],"editor":[{"given":"Marc R","family":"Birtwistle,","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1012839","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}